Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $105
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $75 to $105.
July 29, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Peter Lawson maintains an Equal-Weight rating on Blueprint Medicines and raises the price target from $75 to $105.
The raised price target from $75 to $105 by Barclays suggests a positive outlook for Blueprint Medicines, which could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100